PerpEquities

Pfizer Inc. (PFE) cash flow statement

NYSE · Healthcare · Drug Manufacturers - General · 75,000 employees · CEO Albert Bourla

Price
$30.52 +1.90%
Market cap
$174B
Enterprise value
$236B
Last report
Q2 '26 filed 2026-08-04
Next report
2026-11-03 EPS est. $0.73

In Q2 '26 Pfizer Inc. (PFE) generated $835M of operating cash flow, invested $533M in capital expenditure and kept $302M of free cash flow. Over the last four quarters free cash flow was $11B.

Cash flow

Cash flowTrendQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Operating
Net income-$2.39B-$3.34B$3.13B$31M$4.48B$411M$2.97B$2.9B$3.55B-$1.64B$2.68B-$220M
Depreciation & amortization$1.56B$1.67B$1.74B$1.73B$1.76B$1.79B$1.62B$1.63B$1.66B$1.69B$1.61B$1.62B
Stock-based compensation$151M$121M$220M$206M$274M$177M$170M$203M$201M$225M$272M$249M
Deferred income tax-$113M-$1.86B-$441M-$783M-$482M-$396M-$663M-$272M-$765M-$433M-$12M-$1.32B
Change in working capital-$1.2B$8.45B-$3.34B-$3.54B$879M$2.93B-$1.92B-$4.99B-$36M$1.59B-$1.73B-$1.82B
Other non-cash items$5.45B$192M-$217M$569M-$193M$1.81B$156M-$52M-$10M$3.92B-$209M$2.32B
Operating cash flow$3.46B$5.24B$1.09B-$1.78B$6.71B$6.72B$2.34B-$582M$4.6B$5.35B$2.62B$835M
Investing
Capital expenditure-$810M-$1.04B-$704M-$637M-$651M-$917M-$564M-$618M-$602M-$845M-$436M-$533M
Acquisitions-$2M-$43.4B$3.49B$0$0$3.55B$6.31B-$6.31B$0-$6.93B$0$0
Purchases of investments-$9.21B-$874M-$2.02B$657M-$2.67B-$6.28B-$6.81B-$2.03B-$4.94B-$876M-$2.67B-$2.15B
Sales / maturities of investments$10.6B$34.3B$963M$4.6B$1.26B$2.01B$4.04B$12.9B$3.1B$2.64B$4.66B$2.13B
Other investing$350M$15M$1M-$19M$6M$12M$299M-$9M$12M-$137M-$770M$2.66B
Investing cash flow$888M-$11B$1.73B$4.6B-$2.06B-$1.62B$3.27B$3.95B-$2.43B-$6.15B$785M$2.11B
Financing
Net debt issued / repaid-$1.43B$7.78B-$2.17B-$16M-$2.25B-$2.72B-$2.43B-$731M$6M$3.09B-$127M-$1.19B
Dividends-$2.31B-$2.32B-$2.37B-$2.38B-$2.38B-$2.38B-$2.44B-$2.45B-$2.44B-$2.45B-$2.45B-$2.45B
Other financing (incl. tax on vested shares)-$37M-$18M-$386M-$63M-$6M-$14M-$356M-$20M-$38M-$44M-$284M-$26M
Financing cash flow-$3.78B$5.44B-$4.93B-$2.46B-$4.64B-$5.11B-$5.23B-$3.2B-$2.48B$596M-$2.86B-$3.66B
Summary
FX effect on cash-$32M$19M-$28M-$18M$19M-$29M-$7M$41M$2M$0$19M-$4M
Net change in cash$535M-$295M-$2.14B$343M$40M-$45M$374M$213M-$300M-$201M$563M-$726M
Free cash flow (OCF - capex)$2.65B$4.2B$386M-$2.42B$6.06B$5.8B$1.77B-$1.2B$4B$4.5B$2.18B$302M
Income taxes paid$882M$240M$184M$2.5B$486M-$3.17B$152M$3.34B$178M$1.02B$72M$3.47B
Interest paid$332M$1.06B$415M$1.14B$280M$1.39B$353M$1.13B$275M$981M$293M$1.25B

Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Share count and EPS

quarterly, diluted

The other statements

Sources

Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-28, 10-Q 2026-03-29, 10-K 2025-12-31, 10-Q 2025-09-28, 10-Q 2025-06-29, 10-Q 2025-03-30, 10-K 2024-12-31, 10-Q 2024-09-29, 10-Q 2024-06-30

Data as of 2026-11-01